Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Alissa, Visram"'
Autor:
Alissa Visram, Kelvin Kar-Wing Chan, Hsien Seow, Gregory Pond, Anastasia Gayowsky, Ghulam Rehman Mohyuddin, Arleigh McCurdy, Irwindeep Sandhu, Christopher Venner, Guido Lancman, Amaris Balitsky, Tom Kouroukis, Robert Bruins, Shaji Kumar, Rafael Fonseca, Hira Mian
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/a58990cd39774fcc882a1c883456b5f0
Autor:
Arleigh McCurdy, Hira Mian, Richard LeBlanc, Victor H. Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece, Christopher P. Venner
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-6 (2023)
Abstract While most patients diagnosed with multiple myeloma (MM) receive initial therapy, reported attrition rates are high. Understanding attrition rates and characteristics of patients not receiving subsequent therapy is useful for MM stakeholders
Externí odkaz:
https://doaj.org/article/14c4decaca6e4a0bbfd717e2c08b1751
Autor:
Matthew Ho, Surendra Dasari, Alissa Visram, Matthew T. Drake, M. Cristine Charlesworth, Kenneth L. Johnson, Ganesh P. Pujari, Dragan Jevremovic, Taxiarchis Kourelis
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Multiple myeloma (MM) bone disease is a significant cause of morbidity but there is a paucity of data on the impact of malignant plasma cells on adjacent trabecular bone within the BM. Here, we characterize the proteome of trabecular bone ti
Externí odkaz:
https://doaj.org/article/e4ad50c6f5ef42cca7511e52317523e3
Autor:
Arleigh McCurdy, Hsien Seow, Gregory P. Pond, Anastasia Gayowsky, Rajshekhar Chakraborty, Alissa Visram, Rayan Kaedbey, Anita D’Souza, Ghulam Rehman Mohyuddin, Tanya M. Wildes, Rafael Fonseca, Hira Mian
Publikováno v:
Haematologica, Vol 108, Iss 12 (2023)
Survival has improved in patients diagnosed with multiple myeloma (MM) over the last two decades; however, there remains a paucity of data on the causes of death in MM patients and whether causes of death change during the disease trajectory. We cond
Externí odkaz:
https://doaj.org/article/a9c547f9f3a04a3c841cf27386a94803
Autor:
Sarah Goldman-Mazur, Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Robert A. Kyle, Shaji K. Kumar
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 12, Pp 1-6 (2022)
Abstract The treatment landscape for relapsed multiple myeloma (MM) has increased. In this study, we aimed to characterize 2nd (n = 1439) and 3rd (n = 1104) line regimens and compare the results between subgroups based on the year of treatment initia
Externí odkaz:
https://doaj.org/article/5e9ecee209e245c3b66b41676099aaf1
Autor:
Arleigh McCurdy, Martha Louzada, Christopher P. Venner, Alissa Visram, Esther Masih‐Khan, Moustafa Kardjadj, Victor H. Jimenez‐Zepeda, Richard LeBlanc, Michael Sebag, Kevin Song, Darrell White, Hira Mian, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Rami Kotb, Engin Gul, Donna Reece
Publikováno v:
eJHaem, Vol 3, Iss 4, Pp 1252-1261 (2022)
Abstract Carfilzomib is an active and commonly used treatment in patients with multiple myeloma (MM). Using the Canadian Myeloma Research Group Database, we performed a retrospective observational study of patients treated with carfilzomib for relaps
Externí odkaz:
https://doaj.org/article/1c70a968264b4965a924d97d53f6976e
Autor:
Marisa K. Kilgour, Donald J. Bastin, Seung-Hwan Lee, Michele Ardolino, Scott McComb, Alissa Visram
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have revolutionized treatment for several cancer types over the past decade. Despite this success, obstacles including the high price tag, manufacturing complexity, and treat
Externí odkaz:
https://doaj.org/article/d6af72ff1fde46dbac7e6d107277a392
Autor:
Arleigh McCurdy, Hira Mian, Richard LeBlanc, Victor H. Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece, Christopher P. Venner
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/a0d9c78988334797b5fff861e80eb58a
Autor:
Geffen Kleinstern, Dirk R. Larson, Cristine Allmer, Aaron D. Norman, Grace Muntifering, Jason Sinnwell, Alissa Visram, Vincent Rajkumar, Angela Dispenzieri, Robert A. Kyle, Susan L. Slager, Shaji Kumar, Celine M. Vachon
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-7 (2022)
Abstract Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass
Externí odkaz:
https://doaj.org/article/3f36fbc509cf4678918349c8977d476d
Autor:
Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Linda B. Baughn, Robert A. Kyle, Shaji Kumar
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-8 (2021)
Abstract The Mayo-2018 smoldering multiple myeloma (SMM) risk score is used routinely in the clinical setting but has only been validated at diagnosis. In SMM patients, the progression risk decreases over time. However, the utility of applying risk s
Externí odkaz:
https://doaj.org/article/93d4ece315db4f62bf0683715cca31d3